Covid 19

Jubilant Life Sciences Limited : pro-active, multi-pronged measures to curb the spread of novel Coronavirus (COVID-19)

Given the recent threat by the novel Coronavirus (COVID-19), Jubilant Life Sciences Limited has taken several proactive measures to curb the spread of the contagious virus among its employees and stakeholders. A company-wide awareness campaign was launched with informative emailers. Internal travel advisories have been issued to all employees and all international and domestic travel…

Venom Immunotherapy Supplies

Venom Immunotherapy Supply Update

One year ago, we announced that our company had become the sole provider of venom immunotherapy products in the U.S.—a position brought about by the departure from the market of the only other supplier. In the ensuing year, we have committed all of our resources to ensuring a long-term, consistent supply of venom products for our customers. We’re pleased to share with you this brief overview of what we’ve been working on, and advances CMS has made with reimbursements.

Venom Immunotherapy Supplies

Venom Immunotherapy Supplies

Read as letter Read related AAAAI/ACAAI email to members At the end of February 2018, we learned that we will be the only supplier of venom immunotherapy products in North America. In light of this situation, we have evaluated our production capabilities as they relate to our ability to indefinitely supply the entire North American…